Combining the findings reported here and in our previous publication [15], targeting mTOR signaling could represent a potentially effective therapeutic approach for PHT, ameliorating not only intrahepatic disturbances, but also splenomegaly. The gene discussed is MTOR; the disease is pulmonary hypertension, primary, 1.